Laboratorios Farmaceuticos Rovi (XMAD:ROVI) E10: €2.26 (As of Mar. 2026)


XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
100 GF Score
Price €58.60
GF Value €50.93
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi E10?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -1.10% 100 E10 is €2.26 as of Mar. 2026. GuruFocus rates XMAD:ROVI with a GF Score™ of 100/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.185. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €2.26 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average E10 Growth Rate was 12.40% per year. During the past 3 years, the average E10 Growth Rate was 24.00% per year. During the past 5 years, the average E10 Growth Rate was 33.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Laboratorios Farmaceuticos Rovi was 43.30% per year. The lowest was 21.30% per year. And the median was 34.20% per year.

As of today (2026-06-28), Laboratorios Farmaceuticos Rovi's current stock price is €58.60. Laboratorios Farmaceuticos Rovi's E10 for the quarter that ended in Mar. 2026 was €2.26. Laboratorios Farmaceuticos Rovi's Shiller PE Ratio of today is 25.93.

During the past 13 years, the highest Shiller PE Ratio of Laboratorios Farmaceuticos Rovi was 105.81. The lowest was 24.05. And the median was 43.75.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Laboratorios Farmaceuticos Rovi's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=58.60/2.26
=25.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Laboratorios Farmaceuticos Rovi was 105.81. The lowest was 24.05. And the median was 43.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Laboratorios Farmaceuticos Rovi E10 Related Terms


Laboratorios Farmaceuticos Rovi E10 Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi E10 Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 1.19 1.59 1.98 2.27

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 2.07 2.16 2.27 2.26

XMAD:ROVI vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Shiller PE Ratio falls into.


XMAD:ROVI
100GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.185/128.4016*128.4016
=0.185

Current CPI (Mar. 2026) = 128.4016.

Laboratorios Farmaceuticos Rovi Quarterly Data

per share eps CPI Adj_EPS
201606 0.174 100.333 0.223
201609 0.071 99.737 0.091
201612 0.093 101.842 0.117
201703 0.129 100.896 0.164
201706 0.190 101.848 0.240
201709 0.026 101.524 0.033
201712 0.004 102.975 0.005
201803 0.139 102.122 0.175
201806 0.014 104.165 0.017
201809 0.164 103.818 0.203
201812 0.041 104.193 0.051
201903 0.125 103.488 0.155
201906 0.167 104.612 0.205
201909 0.262 103.905 0.324
201912 0.155 105.015 0.190
202003 0.251 103.469 0.311
202006 0.283 104.254 0.349
202009 0.311 103.521 0.386
202012 0.257 104.456 0.316
202103 0.430 104.857 0.527
202106 0.491 107.102 0.589
202109 0.865 107.669 1.032
202112 0.988 111.298 1.140
202203 0.984 115.153 1.097
202206 0.517 118.044 0.562
202209 0.797 117.221 0.873
202212 1.492 117.650 1.628
202303 0.906 118.948 0.978
202306 0.360 120.278 0.384
202309 0.984 121.343 1.041
202312 1.950 121.300 2.064
202403 0.292 122.762 0.305
202406 0.574 124.409 0.592
202409 1.352 123.121 1.410
202412 1.810 124.753 1.863
202503 0.354 125.531 0.362
202506 0.423 127.251 0.427
202509 1.134 126.842 1.148
202512 0.834 128.402 0.834
202603 0.185 128.402 0.185

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €2.26 mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a E10 of €2.26 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's E10 too high?
Laboratorios Farmaceuticos Rovi's current E10 is €2.26. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's E10 compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's E10 of €2.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current E10 is €2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €58.60 — trading 15.1% above its estimated fair value. The current E10 is €2.26. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current E10 is €2.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €58.60 is trading 15.1% above its estimated GF Value™ of €50.93. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for XMAD:ROVI:

  • E10: €2.26
  • GF Value™: €50.93 vs. price of €58.60 (15.1% above fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score

Get the complete analysis for XMAD:ROVI

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.60
Price
€50.93
GF Value